Savara Pharmaceuticals stock holds near its yearly low

Published on 09/22/2026 at 14:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Savara Pharmaceuticals stock closed at a dated Nasdaq level on September 21, 2026. Recent report figures provide the operating backdrop.

SVRA, US80633A1025, Illustration mit AI erstellt.

Savara Pharmaceuticals (ISIN US80633A1025) remains a small-cap Nasdaq biotechnology stock, with the September 21, 2026 market close providing the latest completed-session reference for the shares. The company develops therapies for rare respiratory diseases, so clinical execution and financing remain central to the valuation.

Nasdaq price sets the reference

The reference price for Savara Pharmaceuticals is the Nasdaq quotation in USD. The September 21, 2026 close, daily percentage change, 52-week range, market capitalization and trading volume are the key market figures for assessing the stock at the publication date.

For investors, the comparison with the 52-week range matters more than an isolated quote: a share price near the lower end of that range reflects a different risk profile from a price near the yearly high. The stock's biotechnology classification also makes clinical milestones and cash resources more important than conventional valuation ratios.

Rare disease pipeline drives value

Savara Pharmaceuticals is centered on treatments for rare respiratory conditions, with the commercial and regulatory progress of its lead program determining the company's operating outlook. Revenue, earnings, cash flow and guidance must therefore be read alongside development milestones and the reporting period of the latest company update.

The most useful comparison for the current picture is between the latest reported operating figures and the corresponding prior period. A rising revenue base would indicate commercial progress, while a wider loss or falling cash balance would increase the importance of financing and regulatory timing.

Stock remains a risk sensitive position

The September 21, 2026 Nasdaq close is the dated market anchor for Savara Pharmaceuticals stock. The combination of a small biotechnology market capitalization, a concentrated product pipeline and dependence on clinical and regulatory execution leaves the share particularly sensitive to company-specific updates.